MAB
Recent news mentioning MAB
- — Deutsche Bank alcanza un acuerdo con un exdirectivo que reclamaba 152 millones
- — vivo and UNESCO MAB Bring Young Voices Together in Italy to Capture the Future
- — Pharmabranche: Novo Nordisk stoppt zwei weitere Studien zu Herzmedikament
- — Pharmabranche: Rückschlag bei Herzmedikament – Novartis-Aktie im Minus
- — Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease
- — Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
- — ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients
- — Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
- — Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
- — RNAV8 Bio Joins Team Selected for ARPA-H Funding to Develop Programmable RNA Medicines
- — Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback
- — New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity